Longitudinal "Real-World" Outcomes of Pirfenidone in Idiopathic Pulmonary Fibrosis in Greece

Argyrios Tzouvelekis; Theodoros Karampitsakos; Paschalis Ntolios; Vasilios Tzilas; Evangelos Bouros; Evangelos Markozannes; Ioanna Malliou; Aris Anagnostopoulos; Andreas Granitsas; Paschalis Steiropoulos; Katerina Dimakou; Serafeim Chrysikos; Nikolaos Koulouris; Demosthenes Bouros

doi:10.3389/fmed.2017.00213

Longitudinal "Real-World" Outcomes of Pirfenidone in Idiopathic Pulmonary Fibrosis in Greece

Front Med (Lausanne). 2017 Nov 29:4:213. doi: 10.3389/fmed.2017.00213. eCollection 2017.

Authors

Affiliations

¹ First Academic Department of Pneumonology, Hospital for Diseases of the Chest "Sotiria", Medical School, National and Kapodistrian University of Athens, Athens, Greece.
² Division of Immunology, Biomedical Sciences Research Center "Alexander Fleming", Athens, Greece.
³ 5th Respiratory Department, Hospital for Diseases of the Chest "Sotiria", Athens, Greece.
⁴ Department of Pneumonology, University Hospital of Alexandroupolis, Democritus University of Thrace, Komotini, Greece.

Abstract

Background: Pirfenidone is an antifibrotic compound able to slow down disease progression in patients with idiopathic pulmonary fibrosis (IPF).

Objective: To investigate the safety and efficacy of pirfenidone in patients with IPF in a real-life setting.

Methods: This was a multicenter, retrospective, real-life, observational study for patients with IPF receiving pirfenidone.

Results: We identified 92 patients with IPF receiving pirfenidone. Eighty patients (70 males and 10 females, mean age ± SD: 68.1 + 7.5, mean %FVC ± SD = 74.9 ± 17.2, mean %DL_CO ± SD = 48.1 ± 16.9) were included in the analysis. Skin-related (25%) and gastrointestinal (17.5%) adverse events were the most common and led to drug discontinuation in 22.5% of cases. The majority (87%) of patients experienced side effects during the first 6 months of treatment. At 36 months, changes in %FVC and %DL_CO were -9.25 ± 16.34 and -9.26 ± 15.26, respectively. At 6, 12, and 24 months after treatment initiation (n = 80, 60, and 26), 18, 15, and 5 patients (22.5, 25, and 19.2%) experienced significant (>10%) and 11, 3, and 3 patients (13.8, 5, and 11.5%) experienced marginal (5-10%) %FVC improvement; and 13, 6, and 1 patient (16.2, 10, and 3.9%) experienced marginal (-5 to -10%) and 20, 21, and 8 patients (25, 35, and 30.8%) experienced significant decline (<-10%) in %FVCpred. Median survival was 851 days, and 41 patients died during the study period.

Conclusion: Pirfenidone demonstrated an acceptable safety and therapeutic profile in patients with IPF on a longitudinal basis. Prospective observational registries are urgently needed to provide a real-world view of outcomes of pirfenidone in clinical practice.

Keywords: efficacy; idiopathic pulmonary fibrosis; pirfenidone; safety; treatment.